Study of the Safety, and Sperm and Gonadotropin Suppression of a Contraceptive Gel in Normal Men (CCN007)
This study has been completed.
Sponsor:
Collaborator:
Population Council
Information provided by (Responsible Party):
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
ClinicalTrials.gov Identifier:
NCT00891228
First received: April 30, 2009
Last updated: December 14, 2012
Last verified: April 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To determine the number of men who have suppression of sperm production when using a daily regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel applied transdermally.
| Condition | Intervention | Phase |
|---|---|---|
|
Contraception |
Drug: Testosterone Drug: Nestorone® |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator) Primary Purpose: Prevention |
| Official Title: | A Multicenter, Randomized, Double-Blind Comparator Trial of the Safety and Sperm and Gonadotropin Suppression Resulting From Combined Use of Nestorone® Gel (0, 8 or 12 mg NES) and Testosterone Gel (10 g) Compared With Testosterone Gel in Normal Men |
Resource links provided by NLM:
MedlinePlus related topics:
Birth Control
Drug Information available for:
Testosterone propionate
Methyltestosterone
Testosterone cypionate
Testosterone
Testosterone enanthate
U.S. FDA Resources
Further study details as provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
Primary Outcome Measures:
- To determine the number of men who have suppression of sperm production ≤1 million/mL when using a daily regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel applied transdermally. [ Time Frame: 24 Weeks ] [ Designated as safety issue: Yes ]
Secondary Outcome Measures:
- To determine the number of men who have suppression of sperm production ≤ 3 million/mL or azoospermia when using a daily regimen of Nestorone® Gel (0, 8 or 12 mg) and Testosterone Gel. [ Time Frame: 24 Weeks ] [ Designated as safety issue: Yes ]
- To determine the level of suppression of gonadotropins caused by transdermal usage of Testosterone Gel and 0, 8, or 12 mg Nestorone® Gel and to correlate the level of gonadotropin suppression with sperm suppression. [ Time Frame: 24 Weeks ] [ Designated as safety issue: Yes ]
- To evaluate the impact on sperm morphology and motility in men who are not azoospermic. [ Time Frame: 24 Weeks ] [ Designated as safety issue: Yes ]
| Enrollment: | 99 |
| Study Start Date: | May 2009 |
| Study Completion Date: | November 2011 |
| Primary Completion Date: | May 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: Testosterone Gel 10 g and Nestorone® 0 mg per day
Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
|
Drug: Testosterone
Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
Drug: Nestorone®
Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
|
|
Experimental: Testosterone Gel 10 g and Nestorone® 8 mg per day
Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg NES mL gel) by pressing two times with 2 mL dispenser head.
|
Drug: Testosterone
Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
Drug: Nestorone®
Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
|
|
Experimental: Testosterone Gel 10 g plus Nestorone® Gel 12 mg per day
Two individual packets of Testosterone Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of Testosterone on the skin. Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
|
Drug: Testosterone
Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
Drug: Nestorone®
Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
|
Eligibility| Ages Eligible for Study: | 18 Years to 50 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria
Men who meet all the following criteria are eligible for enrollment in the trial:
- Male volunteers in good health as confirmed by physical examination, medical history, and clinical laboratory tests of blood and urine at the time of screening
- 18 to 50 years of age
- BMI ≤ 33 calculated as weight in Kg/ (height in cm) 2
- No history of hormonal therapy use in the last six months prior to the first screening visit
- Subject will agree to use a recognized effective method of contraception with his partner (i.e. at a minimum, use double-barrier contraception) during the course of the study treatment and recovery phase
- In the opinion of the investigator, subject is able to comply with the protocol, understand and sign an informed consent and HIPAA form
- Does not meet any of the exclusion criteria.
Exclusion Criteria:
Men who meet any of the following criteria are NOT eligible for enrollment in the trial:
- Men participating in another clinical trial involving an investigational drug within the last 30 days prior to the first screening visit
- Men not living in the catchment's area of the clinic or within a reasonable distance from the site
- Clinically significant abnormal findings at screening
- Elevated PSA (levels ≥ 4 ng/mL), according to local laboratory normal values
- Abnormal serum chemistry values, according to local laboratory normal values that indicate liver or kidney dysfunction or that may be considered clinically significant. Other abnormal lab values may also be exclusionary, at the discretion of the investigator
- Sperm concentration below 15 million/mL in more than one of three screening samples
- Use of androgens or body building substances within 6 months before first screening visit
- Diastolic (D) blood pressure (BP) ≥ 85 and Systolic (S) BP ≥ 135 mm Hg; (BP will be taken 3 times at 5 minute intervals and the mean of all measurements be considered)
- History of hypertension, including hypertension controlled with treatment
- Known history of primary testicular disease or disorders of the hypothalamic-pituitary axis
- Known hypersensitivity to progestins
- Family or personal history of venous thromboembolism
- Benign or malignant liver tumors; active liver disease
- History of breast carcinoma
- Known history of reproductive dysfunction including vasectomy or infertility
- Known history of cardiac, renal, hepatic or prostatic disease
- A serious systemic disease such as diabetes mellitus or morbid obesity (body weight greater than 120% of ideal body weight or BMI limitation as above)
- History of sleep apnea
- Known or suspected alcoholism or drug abuse that may affect metabolism/transformation of steroid hormones and study treatment compliance
- Known dermatitis or severe skin disorder
- Partner is known to be pregnant
- Men desiring fertility within the first 24 weeks of study participation.
Men participating in competitive sports where drug screening for prohibited substances (including anabolic steroids) is routine will be advised of the relative and temporary hazards that participating in this study may have for their fertility or sporting status.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00891228
Locations
| United States, California | |
| Los Angeles Biomedical Research Institute at Harbor-UCLA | |
| Torrance, California, United States, 90502 | |
| United States, Washington | |
| University of Washington | |
| Seattle, Washington, United States, 98195 | |
Sponsors and Collaborators
Population Council
Investigators
| Principal Investigator: | Christina Wang, MD | LA BioMedical Research Institute, Harbor-UCLA |
| Principal Investigator: | William Bremner, MD, PhD | University of Washington |
More Information
No publications provided
| Responsible Party: | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
| ClinicalTrials.gov Identifier: | NCT00891228 History of Changes |
| Other Study ID Numbers: | HSN275200800042U |
| Study First Received: | April 30, 2009 |
| Last Updated: | December 14, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD):
|
Contraception Male Contraception Suppression of Sperm Production |
Additional relevant MeSH terms:
|
Testosterone Testosterone enanthate Testosterone undecanoate Testosterone 17 beta-cypionate Methyltestosterone ST 1435 Androgens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists |
Physiological Effects of Drugs Pharmacologic Actions Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Anabolic Agents Contraceptive Agents, Female Contraceptive Agents Reproductive Control Agents |
ClinicalTrials.gov processed this record on June 17, 2013